» Articles » PMID: 34085554

Up-regulation of CTRP12 Ameliorates Hypoxia/re-oxygenation-induced Cardiomyocyte Injury by Inhibiting Apoptosis, Oxidative Stress, and Inflammation Via the Enhancement of Nrf2 Signaling

Overview
Journal Hum Exp Toxicol
Publisher Sage Publications
Specialty Toxicology
Date 2021 Jun 4
PMID 34085554
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

C1q/TNF-related protein 12 (CTRP12) has been reported to play a key role in coronary artery disease. However, whether CTRP12 plays a role in the regulation of myocardial ischemia-reperfusion injury is not fully understood. The goals of this work were to assess the possible relationship between CTRP12 and myocardial ischemia-reperfusion injury. Here, we exposed cardiomyocytes to hypoxia/re-oxygenation (H/R) to establish an cardiomyocyte injury model of myocardial ischemia-reperfusion injury. Our results showed that H/R treatment resulted in a decrease in CTRP12 expression in cardiomyocytes. The up-regulation of CTRP12 ameliorated H/R-induced cardiomyocyte injury via the down-regulation of apoptosis, oxidative stress, and inflammation. In contrast, the knockdown of CTRP12 enhanced cardiomyocyte sensitivity to H/R-induced cardiomyocyte injury. Further investigation showed that CTRP12 enhanced the levels of nuclear Nrf2 and increased the expression of Nrf2 target genes in cardiomyocytes exposed to H/R. However, the inhibition of Nrf2 markedly diminished CTRP12-overexpression-mediated cardioprotective effects against H/R injury. Overall, these data indicate that CTRP12 protects against H/R-induced cardiomyocyte injury by inhibiting apoptosis, oxidative stress, and inflammation via the enhancement of Nrf2 signaling. This work suggests a potential role of CTRP12 in myocardial ischemia-reperfusion injury and proposes it as an attractive target for cardioprotection.

Citing Articles

Evaluation of Serum CTRP-4 and CTRP-12 Levels in Hashimoto's Thyroiditis Patients: A Comparative Analysis with a Control Group and Their Correlation with Biochemical Factors.

Al-Husseini D, Saravani M, Nosratzehi S, Akbari H, Shafiei A, Jafari S Iran J Pathol. 2025; 20(1):42-48.

PMID: 40060227 PMC: 11887634. DOI: 10.30699/ijp.2024.2025001.3276.


CTRP12 ameliorates post-myocardial infarction heart failure through down-regulation of cardiac apoptosis, oxidative stress and inflammation by influencing the TAK1-p38 MAPK/JNK pathway.

Bai B, Ji Z, Wang F, Qin C, Zhou H, Li D Inflamm Res. 2023; 72(7):1375-1390.

PMID: 37382682 DOI: 10.1007/s00011-023-01758-4.


CTRP family in diseases associated with inflammation and metabolism: molecular mechanisms and clinical implication.

Zhang H, Zhang-Sun Z, Xue C, Li X, Ren J, Jiang Y Acta Pharmacol Sin. 2022; 44(4):710-725.

PMID: 36207402 PMC: 10042840. DOI: 10.1038/s41401-022-00991-7.


CTRP12 alleviates cardiomyocyte ischemia‑reperfusion injury via regulation of KLF15.

Liao B, Tian X Mol Med Rep. 2022; 26(1).

PMID: 35656890 PMC: 9185681. DOI: 10.3892/mmr.2022.12763.